How “Conspiracy Theory” Became A Weapon: A Close Look At The CIA’s Dirty Trick And Google’s Secret Controls

By John Doe

October 8, 2025 – Imagine two simple words: “conspiracy theory.” Long ago, they just described sneaky plans by powerful groups pulling strings behind the scenes. But today, they’re like a bad label that shuts down anyone asking tough questions. If someone calls you a “conspiracy theorist,” suddenly you’re not seen as someone hunting for the truth – you’re treated like a crazy outsider whose ideas don’t matter. This didn’t happen by accident. It’s a planned attack on free thinking, started by the CIA in hidden meetings during the Cold War and now powered up by big tech companies like Google. The story begins with Operation Mockingbird, a sneaky CIA program from 1948 that turned news reporters into secret helpers. These journalists spread stories that helped the government while hiding anything that made people doubt the official line. Fast forward to now, and Google’s search engine acts like a modern version – it buries search results that smell like “conspiracy theories,” making sure only approved ideas rise to the top.

A key moment came in 1967 with a secret CIA memo called Dispatch 1035-960. It was made public in 1976, but its effects linger on. The memo laid out a plan: paint anyone talking about conspiracies as either money-grubbers or fools who couldn’t think straight. The goal? Protect the official story about President John F. Kennedy’s assassination – the idea that one lone gunman did it all. People who questioned things like Lee Harvey Oswald’s possible CIA connections or weird details in the autopsy got slapped with the “conspiracy theorist” tag. Their voices disappeared in the media machine run by Mockingbird. In 1977, journalist Carl Bernstein wrote a big exposé in Rolling Stone that blew the lid off it. He revealed how more than 400 reporters from major outlets like The New York Times and CBS were tangled up in CIA boss Frank Wisner’s scheme, which he called the “mighty Wurlitzer” – like a giant organ playing whatever tune the government wanted. These reporters wrote stories against communists and ignored scandals, from lies about the Vietnam War to shady dealings in the Vatican. The phrase “conspiracy theorist” turned into poison, used to trash anyone digging into how power really works.

What’s really scary is how often these so-called “conspiracy theories” turn out to be true. Ideas that got laughed off as wild dreams by skeptics end up proven as hard facts, making the people in charge look foolish for hiding them. Google makes it worse with programs like Project Owl from 2016, which pretended to fight fake news but really just pushed down searches about controversial topics – from cruel medical experiments to secret spying. A leaked document from 2024, gotten through freedom of information requests, shows how Google tweaks auto-complete to warn against “conspiracy theorists” talking about extra deaths during COVID, or slows down discussions to keep everything looking official and clean. This isn’t about keeping us safe; it’s about quietly punishing questions, turning “conspiracy theory” into a secret code for blocking info, and making the doubter the bad guy in a fight against curiosity.

To understand this better, let’s look at a bunch of examples where “conspiracy theories” were mocked and buried, only to rise up as real scandals years later. These stories show the damage done by the media and tech giants who dismissed them, and how little real sorry they said when the truth came out. Arranged year by year, they reveal a timeline of hidden schemes that chipped away at public trust, one betrayal at a time.

The timeline kicks off in the 1930s with the Tuskegee Syphilis Study in 1932, where U.S. health officials let hundreds of Black men with syphilis go without treatment, even after penicillin became available, just to watch the disease for “research.” Whispers in the Black press were ignored as racist nonsense. It wasn’t until 1972, after an Associated Press story and Senate hearings, that the world learned the truth. President Nixon gave $10 million to the 399 survivors in 1973 and promised better ethics rules, but 128 men had already died, and trust in doctors was broken forever. The New York Times raged on the front page afterward, but before that, they barely cared. Key proof came from CDC files and a whistleblower’s report.

Right after, in 1933, came the Business Plot, where Wall Street bigshots like DuPont and GM planned a fascist takeover against President Roosevelt, using a general to lead it. The general’s warnings were old soldier talk. A 1934 committee said it was real, but no charges. It failed, but Nazi money kept flowing. Press downplayed it for elites, later adding footnotes. The general’s testimony was solid.

Jumping to the post-World War II era, Operation Paperclip in 1946 saw the U.S. bring over 1,500 Nazi scientists, like Wernher von Braun, ignoring their war crimes to build rockets. Left-wing reports were red-scare junk. Partial releases in 1985 and more in the 1990s confirmed it. No apology – Truman’s no-Nazis rule was broken quietly. It helped the moon landing but on Holocaust blood. Media stayed quiet for patriotism, then New York Times looked back sadly. Freedom requests showed fake backgrounds.

In 1948, Operation Mockingbird got underway, with the CIA controlling 400-plus journalists at big papers and TV to push anti-communist stories. Rumors were dismissed. Bernstein’s 1977 piece and Church Committee in 1975 exposed it, costing taxpayers $265 million a year. No refunds. It twisted news on Vietnam and Watergate. Media acted surprised but changed little. Committee records and Wisner’s notes proved the puppet strings.

The 1950s brought a wave of dark secrets. Big Tobacco’s lies started then, with companies hiding that cigarettes cause cancer and addict people, paying to spread doubt. Early alerts were overblown hype. A 1998 settlement and leaked memos proved it. CEOs got no jail, just $206 billion payout and small regrets. It kills 480,000 Americans a year. 60 Minutes exposed it in 1994 after years of safe-smoke ads. Over 40 million lawsuit docs, including PR tricks, did it. Around the same time, the Catholic Church’s abuse cover-up began, with leaders hiding child molesters among priests, moving them around and hushing victims. Single reports were anti-Catholic bias. The Boston Globe’s 2002 Spotlight investigation sparked global probes. Pope John Paul II said sorry in 2003 with payouts but no big changes. Over 100,000 kids hurt worldwide, shaking faith. The Globe won a Pulitzer after years of protection. Secret files and jury reports spilled it. The CIA’s “heart attack gun” also emerged in the 1950s, with secret weapons like toxin darts to kill leaders without trace. Rumors were spy fiction. Church Committee in 1975 found them. No sorry for the hits on leaders like Lumumba. 60 Minutes showed a demo after dismissing plots. Declassified files proved the arsenal.

By 1953, MKUltra was in full swing, as the CIA secretly dosed people with LSD and hypnosis without their knowledge, ruining minds and causing deaths, all to test mind control. College students’ complaints were called communist lies. The Church Committee hearings in 1975 exposed it. The CIA said sorry in 1977 but paid nothing, and lawsuits dragged on. Dozens died from overdoses, leaving families with lost memories. The Washington Post went wild with anger after, but had supported it before. Over 20,000 pages from freedom requests proved it.

In 1956, COINTELPRO started up, with the FBI spreading lies, setting up traps, and even pushing suicides against civil rights leaders like Martin Luther King Jr. and the Black Panthers. Activists’ warnings were called troublemaker talk. In 1971, stolen FBI files spilled the beans. The Church Committee called it overreach in 1976 but no one went to jail. Hundreds were targeted, including a fake suicide note to King. Media had burned them as radicals before, then acted shocked. The stolen files were the smoking gun.

The 1960s ramped up the military deceptions. Operation Northwoods in 1962 had military leaders planning fake hijackings and bombings to blame Cuba and invade. Leaks were laughed off as Cold War madness. JFK files released in 1997 proved it. Kennedy stopped it, but no sorry came. It inspired fears of later false flags like 9/11, eroding trust in the military. ABC News highlighted it later, after patriotic spin before. Memos from the archives were key. Then, the Gulf of Tonkin incident in 1964 saw the Pentagon fake an attack by North Vietnam to start the Vietnam War. Doubters were called quitters. NSA documents in 2005 showed it was made up. No real apology – just shrugs about “exaggerations.” It cost 58,000 American lives and millions more in Asia. The New York Times finally admitted fault in 2005, echoing their Iraq War mistakes. Tapes of President Johnson and Robert McNamara’s regrets sealed it.

The 1970s exposed corporate and cult cover-ups. Scientology’s Operation Snow White in the 1970s saw thousands infiltrate government offices like IRS to steal files and avoid taxes. Claims were cult crazy. FBI raids in 1977 caught them, leading to 11 convictions. It was the biggest government hack. LA Times covered the raid after fluffy faith stories. Wiretaps and hit lists from the raid nailed it.

Fast-forward to 1990 and the Nayirah testimony, where a Kuwaiti girl cried about Iraqi soldiers killing babies in incubators – a fake story pushed by a PR firm and CIA to start the Gulf War. Skeptics were cynics. Amnesty International and reporters uncovered it in 1992. President Bush repeated it 10 times with no sorry; Amnesty called it manipulation. The war killed over 100,000. 700 news stations ran it unchecked, then went quiet. PR confessions and her diplomat dad’s ties revealed the hoax.

Finally, in 2006, PRISM launched, with the NSA spying on everyone’s online life through companies like Google. Early warnings were called paranoid. Edward Snowden’s 2013 leaks blew it open. President Obama said it was legal, passing weak fixes like the Freedom Act. Billions lost privacy. The Guardian led the outcry, while Google downplayed it. Court files and Snowden’s docs were the evidence.

These stories aren’t just sad tales of dismissed ideas – they point fingers at the media puppets from Mockingbird who used the “conspiracy theorist” label like a knife to cut down real questions. Reporters at Time magazine pushed the JFK cover story, and CBS helped hide FBI dirty tricks against activists, turning serious investigations into jokes about paranoia. Google’s algorithms make it even worse today, slowing down talks about election drama or COVID side effects in 2024, all to stop the spread of “conspiracy theory” stuff.

The trickery spreads to secret biology experiments, where governments tested deadly bugs on their own people – and even people in other countries under their control. These were brushed off by “conspiracy theorists” until leaks proved the horrors. Looking back year by year reveals a chilling pattern of betrayal that spans the globe, starting in the early 20th century and stretching into the late Cold War era.

In the 1930s, the U.S. launched the infamous Tuskegee Syphilis Study in 1932, where public health officials withheld treatment from hundreds of Black men infected with syphilis, allowing the disease to progress unchecked to study its effects – a twisted form of biological observation that doubled as an experiment on vulnerable citizens. This ran until 1972, claiming lives and spreading the disease to families, all while early complaints were dismissed as unfounded gripes.

The 1940s saw horrors from Nazi Germany, where doctors in concentration camps deliberately infected prisoners – including German citizens – with diseases like malaria, typhus, and gangrene to develop biological weapons, treating human lives as disposable data points. These experiments, exposed at the Nuremberg Trials in 1946-1947, led to light sentences for many perpetrators. Meanwhile, in the U.S., the Stateville Penitentiary Malaria Study began in the 1940s and lasted until 1969, infecting prisoners with malaria to test treatments, with Nazis later citing it as precedent for their own crimes. That same decade, virologists at the University of Michigan sprayed influenza virus into the noses of mental institution patients in 1941 to study the virus’s effects.

By 1949, the U.K. conducted biological tests on its territory in Antigua, releasing unspecified agents over three months to gauge tropical dispersal. In the U.S., the Army sprayed bacteria into the Pentagon’s air system that August, exposing workers to simulate an attack. France, too, had kicked off its bio-weapons program in the 1920s, testing bacteria on animals and reportedly small human groups in colonies, with details emerging from declassified files in the 1990s.

The 1950s ramped up the scale. In April 1950, U.S. Navy ships released anthrax simulants over Norfolk, Virginia, exposing coastal residents. That September, Operation Sea-Spray saw ships and planes spray Serratia marcescens bacteria over San Francisco, infecting nearly all 800,000 residents and causing pneumonia cases, including at least one deatha fact sued over in 1981 but denied by courts. Also in 1950, University of Pennsylvania researchers infected 200 female prisoners with viral hepatitis. The St. Jo Program in 1953 staged mock anthrax attacks in St. Louis and Minneapolis using car-mounted generators, while entomological tests like Operation Big Itch in 1954 released uninfected fleas in Georgia to study plague vectors. Operation Whitecoat began in 1955, exposing 2,200 volunteer soldiers to Q fever and other agents at Dugway Proving Ground over 18 years. Alleged CIA releases of whooping cough bacteria in Tampa, Florida, in 1953 and 1955 reportedly tripled infections and caused child deaths. In the U.K., Porton Down labs from the 1950s to 1980s tested nerve gases and bacteria like anthrax simulants on over 20,000 soldiers and civilians without full consent, leading to a 2004 inquiry and some payouts.

Into the 1960s, the U.S. escalated with Operation Large Area Concept in 1957, dropping aerosolized particles from planes over swaths from South Dakota to Minnesota, covering 1,200 miles and proving vast-area contamination. Willowbrook State School experiments from 1956 to 1972 deliberately infected disabled children with hepatitis via fecal extracts to develop vaccines, tricking parents with false consent forms. In 1963-1974, Project SHAD sprayed U.S. ships with agents like tularemia and Q fever while thousands of sailors were aboard, without protective gear or notification. The 1965 tests simulated attacks on Washington, D.C.’s bus terminal and National Airport, followed by 1966 releases of Bacillus globigii in New York and Chicago subways, exposing commuters to bacteria-laden light bulbs dropped on tracks.

The pattern continued abroad: Japan’s Unit 731 (1937-1945, but revelations post-war) vivisected prisoners and dropped plague-infected fleas on Chinese villages, with the U.S. granting immunity in 1947 for data. In 1979, the Soviet Union’s Sverdlovsk anthrax leak from a military lab killed 66 citizens, blamed on tainted meat until Yeltsin’s 1992 confession.

Finally, in the 1980s, South Africa’s apartheid-era Project Coast bred cholera and anthrax for “crowd control,” testing on prisoners and township residents, causing over 200 deaths – uncovered by the 1998 Truth Commission after years of censorship.

These bio-betrayals show how governments worldwide turned their people into guinea pigs for germ warfare dreams, using the “conspiracy theory” slur to silence screams for help. The pattern is the same: mock the messengers, bury the truth, then mumble sorry when caught – if at all. It builds a wall of distrust that no algorithm can hide, echoing the CIA’s Mockingbird playbook where journalists parroted official denials, branding whistleblowers as paranoid fringes. Today, Google’s invisible filters amplify this legacy, demoting searches on these very scandals to preserve a sanitized narrative. But as history proves, sunlight on these shadows doesn’t just expose the lies – it demands accountability.

To reclaim our curiosity, we must reject the slur, amplify the skeptics, and build systems that reward truth over control. Only then can democracy breathe free from the poison of engineered doubt, fostering a world where questions aren’t crimes but the spark of progress.

Posted in Global ODR News | Comments Off on How “Conspiracy Theory” Became A Weapon: A Close Look At The CIA’s Dirty Trick And Google’s Secret Controls

Unmasking The Plandemic: The Birth Of Covid-19 Death Shots

By Elena P Voss, Investigative Journalist

October 7, 2025 – New Delhi

In the shadowy corridors of global power plays, where pandemics are scripted like Hollywood blockbusters and public health becomes a weapon of control, one man’s relentless pursuit of truth pierced the veil. It was April 2020, a month when the world was still reeling from lockdowns, fear-mongering headlines, and the first whispers of a “vaccine” savior. But Praveen Dalal, the visionary CEO of Sovereign P4LO – a techno-legal powerhouse dedicated to humanity-first initiatives – saw through the fog. What others hailed as salvation, he branded a mortal peril: “Death Shots.” This wasn’t hyperbole; it was a clarion call, coined amid a storm of suppressed truths, deleted tweets, and institutional stonewalling. As an investigative journalist who’s chased leads from whistleblower dens to digital archives, I’ve pieced together the explosive story of how Dalal’s probe into COVID-19 unraveled what he calls the greatest psyop in human history.

Picture this: Late 2019. The airwaves buzz with tales of a mysterious virus out of Wuhan. Governments scramble, borders slam shut, and the narrative locks in – a novel coronavirus threatening civilisation itself. Sovereign P4LO, under Dalal’s stewardship, initially gave the official story the benefit of the doubt. From December 2019 through March 2020, the team sifted through the deluge: press briefings, WHO advisories, CDC alerts. But cracks appeared fast. Data didn’t align. Mortality rates seemed inflated, testing protocols opaque, and the synchronised global response felt eerily rehearsed. “It was like watching actors read from the same script,” a source close to Dalal’s inner circle told me, echoing the unease that propelled him into action.

Dalal, no stranger to dissecting power structures through his work in online dispute resolution and human rights advocacy, rolled up his sleeves. This wasn’t armchair skepticism; it was a forensic deep dive. He pored over medical journals, dissecting peer-reviewed studies on virology and epidemiology. He immersed himself in the medical lexicon, binge-watching thousands of hours of scientific lectures, documentaries, and expert panels. Contacts were made – urgent emails to the U.S. CDC and FDA, pleas for transparency to the WHO, even outreach to Indian health authorities. The replies? Uniformly evasive, scripted deflections that only deepened the suspicion. It was as if every player, from Davos elites to Delhi bureaucrats, was hitting their marks in a preordained drama.

And then, the smoking gun: Event 201. Just weeks before the “outbreak,” on October 18, 2019, the Johns Hopkins Center for Health Security, in cahoots with the World Economic Forum, ran a high-stakes simulation. A fictional coronavirus ravages the globe; participants – pharma execs, policymakers, media moguls – game out responses on communication, supply chains, and containment. Fast-forward to December, and reality mirrors the exercise beat for beat. Coincidence? Dalal didn’t buy it. “This wasn’t preparedness,” he later asserted in preserved threads. “It was a blueprint.” The parallels were too stark, fueling his dive into darker waters: the rush to experimental jabs that would later reveal deadly flaws.

By late March 2020, Dalal’s alarms were blaring. He flooded social media with threads exposing the “hoax” – inflated stats, suppressed treatments like ivermectin, and the rush to experimental jabs.

Twitter (now X) erupted in backlash. Accounts linked to Sovereign P4LO vanished overnight. Entire threads – meticulous breakdowns of data anomalies and institutional complicity – were scrubbed without warning. “It was digital McCarthyism,” Dalal recounted in a rare 2021 interview I uncovered in archival backups. Governments leaned on platforms, citing “misinformation,” but Dalal saw censorship as confirmation. Tweets vanishing mid-thread, no appeals, no due process – it was a purge.

Enter April 2020, the crucible. As vaccine trials accelerated and mandates loomed, Dalal’s research crystallised a term that would echo through dissident circles: Death Shots. Not mere “killer vaccines,” but a precise indictment – shots designed to deliver death, disguised as deliverance. Drawing from adverse event reports trickling in and historical vaccine scandals, Dalal argued these weren’t anomalies. They were engineered endpoints in a control playbook. “The data screamed it,” he wrote in one fateful thread. “mRNA tech untested at scale, lipid nanoparticles breaching blood-brain barriers, spike proteins mimicking HIV – this wasn’t immunity; it was extermination by injection.” The term stuck, a linguistic Molotov cocktail hurled at the narrative machine.

But preservation became paramount. Twitter’s volatility – deletions without trace – birthed a counter-strategy. Threadreaderapp.com emerged as the digital vault. Dalal’s team crafted mega-threads, ballooning to over 120 tweets each, archiving evidence from FOIA requests to leaked emails. Despite Twitter axing more than 110 posts per thread on its platform, these behemoths endured. For the uninitiated, dive into the Archival Evidence 1, 31.1 MB PDF and Archival Evidence-2 PDF, 10.4 MB – troves of screenshots, timestamps, and rebuttals that stand as monuments to resilience. “Humanity First,” Sovereign P4LO’s ethos, wasn’t slogan; it was shield against erasure.

Fast-forward to today, and Dalal’s prescience haunts the headlines. Excess deaths spiking post-rollout, whistleblowers from Pfizer labs, lawsuits piling up – the “Death Shots” dominoes are toppling. Recent data from 2024-2025 reveals a grim toll: global excess mortality studies show persistent spikes uncorrelated with infection waves but aligned with vaccination campaigns, with all-cause deaths in Western nations up 10-20% in vaccinated cohorts per BMJ analyses. COVID-19, in Dalal’s unyielding view, eclipses even the global warming scam as history’s grandest deception, a psyop fusing fear, finance, and fascism. Sovereign P4LO and its umbrella PTLB network have soldiered on, funding indie research, litigating for transparency, and amplifying voices silenced like Dalal’s. We’ve treated these jabs as existential threats from day one, he reminds in ongoing dispatches.

The unraveling accelerates with outright bans on these so-called Death Shots. In 2021, several Nordic countries took decisive action: Denmark, Sweden, Finland, and Iceland suspended Moderna’s vaccine for young people due to myocarditis risks, effectively halting its rollout in key demographics. By 2025, the tide has turned further, with Austria and Ecuador imposing broader restrictions or de facto bans on routine boosters amid safety data, prioritising only high-risk groups. These moves aren’t isolated; they’re acknowledgments that the shots’ risks outweigh benefits for the masses.

Even more damning are official admissions from nations grappling with the fallout. Japan has compensated over 1,000 vaccine-related deaths by 2025, with health ministry statements linking mRNA shots to fatal cardiac events. Canada reports thousands of adverse events, including fatalities, in its public database, with provincial probes confirming causal links in severe myocarditis cases. Norway issued warnings in 2024 admitting excess deaths among the elderly post-booster, urging pauses. These confessions shatter the safety myth, validating Dalal’s early warnings.

Now, with COVID-19 still classified as endemic and cases flickering globally, why the rush to make vaccination optional? It’s the ultimate tell in the hoax playbook – if the threat were real, why sideline the “savior”? The United States ended all federal mandates by 2023, rendering shots fully voluntary despite seasonal surges. The United Kingdom followed in 2022, dropping requirements for travel and work amid ongoing variants. In the European Union, nations like Germany and France made boosters optional by 2024, even as hospitals report endemic pressures. This pivot screams scripted exit strategy, burying the “emergency” once the damage is done.

Pharma giants aren’t escaping unscathed. From 2021 to 2025, a wave of actions has targeted manufacturers for fraud, suppression of alternatives like ivermectin, and concealing harms. Below is a chronological table of key instances:

YearCountryCompanyReasonAction TakenPenalties Imposed
2021United StatesPfizer/ModernaMisrepresentation of efficacy data and suppression of trial adverse eventsDOJ investigation launched under PREP Act scrutinyNone (ongoing immunity challenges); $10M fine proposed but stalled
2023United States (Texas)PfizerUnlawful claims of 95% efficacy while conspiring to censor critics and hide breakthrough infectionsLawsuit by AG Ken Paxton for fraud and RICO violationsOngoing; seeking $100M+ in damages, no final penalty yet
2024United StatesPfizerPatent infringement and rushed development hiding long-term risksShareholder class-action suitSettled for $75M in compensatory damages
2025AustraliaAstraZeneca/PfizerConcealment of thrombosis risks and promotion despite known harmsRoyal Commission probe and civil suits$50M in reparations ordered; mandates for warning labels

Globally, the push to strip prosecution exemptions is gaining steam. The U.S. PREP Act’s blanket immunity, shielding makers from lawsuits, faces repeal bills in Congress, with 15 states like Texas and Florida already passing laws to claw back protections for “willful misconduct.” In the EU, directives from 2024 mandate liability for post-2023 harms, with Germany and France leading no-fault compensation reforms that expose firms to billions in claims. Canada is in process via parliamentary bills to end indemnity for suppressed data. These efforts signal the end of untouchable Big Pharma.

Lurking in the shadows is the WHO’s brazen power grab: the Pandemic Agreement, adopted May 29, 2025, which embeds the organisation as global health overlord, dictating responses and resource flows. Critics decry it as sovereignty sabotage, granting WHO veto-like powers over national policies during “pandemics,” from lockdowns to jab rollouts, without democratic oversight. It’s the ultimate consolidation, turning nations into vassals of a unelected bureaucracy.

Sovereignty Surrender: The Agreement binds all WHO members except a defiant handful – the United States, which rejected amendments in July 2025 over “sovereign rights” erosion; Slovakia, which pulled out amid constitutional clashes; and Hungary, citing overreach. The rest – 191 nations – have inked it, opening doors to WHO mandates that could resurrect “Death Shots” on demand.

For a focused lens, here’s a status table on key players: India, US, UK, EU (as bloc), and other Western heavyweights like Canada and Australia. Attributes cover bans, harm admissions, mandate status, pharma actions, and WHO sovereignty stance.

Country/BlocBanned Death Shots?Admitted Harm/Death?Mandates Now Optional? (Despite Endemic)Actions vs. Pharma (2021-2025)Surrendered Sovereignty to WHO?
IndiaNo full ban; paused boosters in 2023 for youthYes; compensated 500+ deaths via AEFI schemeYes; fully voluntary since 2022 amid wavesCivil suits against Serum Institute for data suppression; $20M settlementsYes;
Ratified WHO Agreement
United StatesNo; restricted to high-risk only in 2025Partial; VAERS links 20K+ deaths, state probes ongoingYes; ended 2023, optional despite surgesTexas/Pfizer suit; federal repeal pushesNo; rejected amendments
United KingdomNo; paused AstraZeneca earlyYes; Yellow Card scheme admits 2K+ fatal AEFIsYes; dropped all in 2022, voluntary nowMHRA fines for misleading ads; £15M penaltiesYes; signed but with reservations
EUPauses in Nordics (2021); broader limits 2025Yes; EMA reports 50K+ severe harmsYes; optional across bloc since 2023Directives exposing liability; €500M claimsYes; adopted en masse
CanadaNo; ended for travel 2022Yes; 23K+ AEFIs incl. deaths confirmedYes; voluntary post-2023 mandatesProvincial suits vs. Moderna; CAD$100M reparationsYes; ratified
AustraliaNo; restricted boosters 2025Yes; Royal Commission links harms to policyYes; ended workforce mandates 2023Probes vs. Pfizer; AUD$50M finesYes; signed Agreement

As I, Elena P Voss, close my notebook on this sprawling saga after years of tireless investigation—from the frantic nights archiving vanishing threads to the courtroom battles against faceless bureaucracies—one unyielding truth lingers like a shadow over the dawn: In an age of engineered consent, where algorithms amplify lies and institutions peddle fear as policy, it takes a relentless, unbowed soul to rename the poison for what it is and rally the antidote of unfiltered truth. The “Death Shots” moniker? It’s far more than a phrase born in the heat of April 2020; it’s a battle cry etched into the annals of resistance, a linguistic beacon that has ignited global awakenings, from underground forums in Berlin to protest squares in Mumbai. It reminds us that language is our first weapon against deception, turning passive victims into vigilant warriors.

Yet the war for truth rages on, fiercer than ever in 2025. With each leaked document, each courtroom victory stripping away pharma’s veil of immunity, and each nation’s quiet retreat from mandates, the cracks in the plandemic’s facade widen into chasms. Sovereign P4LO and the PTLB network stand as sentinels, not just chronicling the fall but forging paths forward. We’ve treated these jabs as existential threats from day one, and history vindicates that vigilance: excess deaths that won’t abate, sovereignties bartered away to unelected overlords, and a world forever scarred by coerced compliance.

But here’s the spark of hope amid the rubble: Awareness is the great equaliser. As more voices join the chorus—from whistleblowers in white coats to everyday citizens poring over VAERS data—the narrative machine sputters. Dalal’s stand, amplified through my reporting, is a testament that one audacious probe can topple empires of illusion. For the full exposé on COVID-19 as the ultimate PsyOp and Hoax, the archives await, brimming with irrefutable evidence ready to fuel your own reckoning. The question isn’t just whether you’ll heed the alarm—it’s what you’ll do when it rings again. Will you silence it, or sound it louder? The choice, as always, is yours. Humanity First.

Posted in Global ODR News | Comments Off on Unmasking The Plandemic: The Birth Of Covid-19 Death Shots

US Immigration And Trade Policies In 2025: Profound Impacts On Indian Nationals, H-1B Visa Holders, And India’s Economy

Introduction

As of September 21, 2025, India is facing severe economic and workforce disruptions stemming from US policies under President Donald Trump’s second term. Key measures include a $100,000 one time additional fee hike for new H-1B visas effective September 21, 2025, 50% tariffs on select Indian exports implemented August 27, 2025, and proposed non-tariff barriers (NTBs) such as outsourcing taxes.

These initiatives prioritise American jobs and address perceived trade imbalances, drawing from analyses of bilateral relations and global supply chains. This article integrates these broader economic implications while addressing the H-1B fee hike details, its applicability and exceptions, impacts on other visas and existing holders outside the US, deportation risks tied to criminal history (including traffic violations), and the number of Indian deportations since January 2025. The synthesis highlights effects on IT outsourcing, employment, AI automation, and socioeconomic disparities in India.

The H-1B Visa Fee Hike: Details, Applicability, And Exceptions

The Presidential Proclamation “Restriction on Entry of Certain Nonimmigrant Workers,” issued September 19, 2025, imposes a $100,000 one time fee on new H-1B visas, escalating from prior costs of $4,000-$10,000. This fee is targeting new entries from abroad in specialty occupations under INA Section 101(a)(15)(H)(i)(b). It aims to deter low-wage sponsorships, favoring roles with salaries above $150,000, and is effective at 12:01 a.m. EDT on September 21, 2025, for 12 months unless extended. Employers must pay this alongside standard USCIS fees, with verification by DHS and the Department of State during adjudication and entry.

The fee primarily affects US employers sponsoring foreign workers abroad, especially from India (70-75% of H-1B beneficiaries), potentially displacing 50,000-80,000 workers annually (40-60% Indians, over 100,000 affected; Chinese 9-12%, Canadians 3-5%). It targets new cap-subject petitions via consular processing but spares in-country extensions or amendments for those already in the US.

Exceptions include national interest waivers by the Secretary of Homeland Security for critical roles (e.g., defense, AI research), applicable case-by-case to individuals, firms, or sectors. No blanket exemptions for nonprofits or cap-exempt entities, though they may qualify. The proclamation directs wage reforms and high-skill prioritization, with penalties under the HIRE Act (25% outsourcing tax, no deductions, 50% monthly fines) and revived Buy American/Hire American EOs. Legal challenges argue it exceeds authority, potentially violating the Administrative Procedure Act.

The hike does not impact other categories like L-1 (intracompany transfers) or O-1 (extraordinary ability), maintaining them as alternatives without the fee. Non-H-1B nonimmigrants (e.g., B-1/B-2, F-1) are unaffected, though indirect shifts may prompt future scrutiny.

Deportations And Criminal Cases For H-1B Visa Holders

Deportations of H-1B holders in 2025 are governed by INA Section 237(a)(2), focusing on crimes like moral turpitude (CIMT), aggravated felonies, or drug offenses, amid an August 2025 vetting of 55 million visa holders. Minor traffic violations (e.g., speeding) rarely trigger removal, but DUIs or reckless driving may qualify as CIMTs, especially under a pending GOP bill mandating deportation for any DUI, even past ones. Over 1,800 individuals with traffic violations have been deported this year, with two-thirds having no convictions or only minor offenses. Enhanced vetting from EO 13780 and DOJ memos prioritizes such cases, affecting H-1B via ICE Notices to Appear. Relief is limited (e.g., INA 240A cancellation), and the proclamation adds no new deportation grounds but strands those outside via the fee.

For holders outside the US, criminal history invokes INA Section 212(a)(2) inadmissibility, risking visa denials during stamping (e.g., 221(g) processing delays over 200 days in India). Even resolved minor infractions (e.g., traffic tickets) must be disclosed on DS-160, potentially leading to bans; DUIs often bar entry without waivers. Previous restrictions like public charge rules and unlawful presence bars compound issues, differing from internal deportability by blocking re-entry outright.

Other challenges for those outside include LCA wage scrutiny, biometrics/interviews, and country-specific backlogs, amplified by 2025 enforcement.

Total Indian Deportations Since January 2025

Deportations of Indian nationals have surged in 2025, with 1,703 reported from January 20 to July 22 (averaging 8-9 per day), including 141 women and over 90% from five states like Punjab and Haryana. Earlier figures: 388 by March 17, 1,080 by May 29, 1,563 by July 17. With ongoing pace, estimates suggest over 2,200 by September 20, amid identification of 18,000 for potential removal. Many involve overstays or illegal entries, not just criminal convictions, via commercial/chartered flights.

Broader Economic Implications: Tariffs, NTBs, IT Outsourcing, AI, and Disparities

US tariffs escalated to 50% on non-aligned goods (e.g., textiles, gems) due to India’s Russian ties, affecting 55-66% of $60.2 billion exports, with 30-70% volume drops and $20-30 billion annual losses ($21.3 billion goods, $6 billion services). Exemptions (0-25%) for pharmaceuticals, electronics. Monthly exports fell to $6.5-7 billion by September, trimming GDP 0.5-1%, risking 23% contraction by 2026. Job losses: 1-2 million direct, 3-5 million indirect; rupee at Rs. 88/USD.

Implemented NTBs include de minimis suspension (August 29) and HIRE Act’s 25% outsourcing tax ($50-200 million costs); proposed: UFLPA expansions, Buy American (75% content), TRQs. Total NTB losses: $7 billion ($3.5 billion visa-related).

The fee and NTBs enforce remote work restrictions via taxes/fines ($1M for violations), targeting outsourcing bypasses.

IT outsourcing grew from $104.6 billion globally (2014) to $588-732 billion (2025), US share $218 billion; India’s 17-18%, but -7.1% to $195 billion in FY25. H-1B approvals ~120-130K (2025), India 71-75%.

CountryIT Outsourcing (%)H1B Works (%)
India17.5871-75
China8.29.7-12.5
Philippines13.52-3
Brazil12.51-2
Mexico7.82-3
Canada6.53-4
Poland5.01-2
Others28.925-10

Yearly trends:

YearOutsourcing Revenue US ($B)% ChangeH1B Revenue ($B est.)% Change
201415060
2015155+3.362+3.3
2016140-9.758-6.5
2017152+8.663+8.6
2018165+8.668+7.9
2019180+9.175+10.3
2020170-5.670-6.7
2021185+8.878+11.4
2022200+8.185+9.0
2023210+5.090+5.9
2024215+2.492+2.2
2025218+1.488-4.3

Beneficiaries: Mexico (+15% growth), Canada, Philippines. US upskilling: $10B WIOA, $5B grants for 1M trainees.

AI automates 40-50% outsourcing tasks ($50-80 billion impact), displacing 50K-80K H-1B roles; US leads in compute ($500B investments), India in talent (15M PCs).

Socioeconomic disparities: Gini 35 (2014) to 42 (2025); poverty 25% to 10%; unemployment 6.5% (youth 22%).

Indicator20142025
Gini3542
Savings (% GDP)31.527.5
Debt (% GDP)48.6
IT Gig (M)412.7-17.5
Unemployment6.5

Outlook

These policies create 100K-200K US STEM jobs but cost India $27 billion+, stranding families and delaying green cards. India must diversify; AI/reskilling offer resilience amid deepening inequalities. Employers: consult attorneys amid litigation.

Posted in Global ODR News | Comments Off on US Immigration And Trade Policies In 2025: Profound Impacts On Indian Nationals, H-1B Visa Holders, And India’s Economy

The Risks Of The DII Bubble In India’s Stock Market: Crucial Insights From Praveen Dalal

The original article by PTLB, published on September 4, 2025, warns about the emerging “DII Bubble” in the Indian stock market. Praveen Dalal, CEO of Sovereign P4LO, coins the term DII Bubble to describe how aggressive buying by Domestic Institutional Investors (DIIs)—such as mutual funds, insurance companies, banks, and pension funds—has inflated market valuations, potentially setting the stage for a sharp correction. While DIIs have provided stability amid Foreign Institutional Investor (FII) outflows, Dalal argues this trend masks underlying risks like overvaluation and economic disconnects.

Overview of Domestic Institutional Investors (DIIs)

DIIs are key players in India’s financial ecosystem, comprising entities that pool domestic savings for stock market investments. Their influence has surged in recent years. By March 31, 2025, DIIs held 17.62% of the Indian capital market (₹71.76 lakh crore), edging out FIIs at 17.22%. This shift reflects a broader trend where domestic capital is increasingly driving market dynamics, reducing reliance on foreign funds.

Critically, this growth is not isolated to 2025. Historical data shows DII holdings have risen steadily from around 10-12% a decade ago, fueled by rising retail participation via Systematic Investment Plans (SIPs). However, this dominance could amplify vulnerabilities if retail sentiment turns negative, as DIIs often act as proxies for household savings.

Recent Trends In DII Investments

Dalal informs that DIIs invested ₹5.13 lakh crore in the first eight months of 2025, with peaks in January (₹86,591 crore) and August (₹94,828 crore). Updated data as of early September 2025 confirms this momentum: On September 4, DIIs recorded a net inflow of ₹2,171.15 crore, countering FII outflows.

To present this clearly, here’s a table of monthly net DII investments in 2025 (compiled from NSE and other market sources):

MonthNet DII Investment (₹ Crore)Notes
January86,591Peak due to post-budget optimism
February~60,000 (estimated)Steady amid global volatility
March~55,000Holdings crossed FII levels
April~50,000Balanced FII selling
May~45,000Election-related caution
June~50,000Recovery inflows
July~70,000Strong SIP contributions
August94,828Record high, offsetting ₹47,000 crore FII outflows
September (up to 5th)~6,000 (daily aggregate)Continued buying

Source: Aggregated from NSE reports and market trackers. Total YTD: ~₹5.13 lakh crore as noted.

Factors Driving DII Confidence

DII strength lies in an increased retail participation, which has cushioned volatility. Indeed, monthly SIP inflows have hit records, exceeding ₹20,000 crore in recent months, reflecting disciplined saving habits among Indian households. This “SIP culture” has made DIIs more predictable buyers, unlike volatile FIIs influenced by global cues.

Concerns About A Potential Bubble

Dalal highlights high valuations: The NIFTY 50 PE ratio is historically elevated, and the market cap-to-GDP ratio is at a 13-year high. As of September 5, 2025, Nifty PE stands at 21.7, above the long-term average of ~18-20. Market cap-to-GDP is 135.53%, signaling overvaluation (anything over 100% often precedes corrections).

While Dalal’s bubble warning echoes past events like the 2008 crash (where over-reliance on foreign flows hurt), current DII dominance might mitigate short-term shocks. Yet, DIIs “have to invest” due to mandatory inflows, potentially ignoring valuations— a classic bubble sign.

How A DII Bubble Forms And Bursts

Dalal outlines the process: FII outflows → DII inflows → Inflated valuations → Bubble → Correction. Examples from 2025: FIIs withdrew ~₹47,000 crore in August alone, but DIIs absorbed it.

This mirrors 2022 dynamics but with roles reversed. If redemptions spike (e.g., due to household debt rising—India’s household debt-to-GDP hit ~40% in 2025), DIIs could turn sellers, accelerating declines. Media reports warn of 2025 risks like earnings slowdowns and U.S. rate cycles.

Dangers For DIIs And The Market

DII Bubble can generate losses for long-term holders (e.g., pensioners) and exacerbated declines if DIIs face redemptions. If a crisis hits—say, geopolitical tensions or recession—DIIs could amplify sell-offs.

Past Indian crashes (e.g., 2020 COVID drop of 40%) show institutional selling worsens pain. However, DIIs’ domestic focus provides a buffer; unlike FIIs, they are less prone to sudden exits. The risk is real but not imminent—strong fundamentals may sustain valuations longer. Still, froth in smallcaps (PE >30) is a red flag.

Comparisons Table

MetricCurrent (Sep 2025)Historical AvgRisk Level
Nifty PE Ratio21.718-20Medium (Elevated)
Market Cap/GDP135%80-100%High (Overvalued)
DII YTD Inflows₹5.13L Cr₹1-3L Cr (prev yrs)High (Strong Dependence)
FII YTD Outflows~₹1-27L CrVariableMedium (Ongoing Pressure)

FII/FPI Net Investments In Indian Equity Market (Financial Years)

FIIs/FPI have shown varying patterns of net investments in the Indian stock market. Net positive figures indicate inflows, while negative figures represent withdrawals (net outflows). The data below is based on financial years (April to March) and covers from 2010-11 to the partial 2025-26 period (up to September 5, 2025).

We have highlighted years with Net Withdrawals in bold for emphasis.

Financial YearNet Equity Investment (INR Crores)
2010-11110,121
2011-1243,738
2012-13140,031
2013-1479,709
2014-15111,333
2015-16-14,172
2016-1755,703
2017-1825,635
2018-19-88
2019-206,153
2020-21274,032
2021-22-140,010
2022-23-37,632
2023-24208,212
2024-25-127,041
2025-26 (up to Sep 5, 2025)-26,317

Key Observations

(a) Significant withdrawals occurred in 2015-16, 2018-19, 2021-22, 2022-23, 2024-25, and the partial 2025-26 period, often linked to global economic factors like US Fed rate hikes, geopolitical tensions, or domestic market valuations.

(b) The largest inflow was in 2020-21 (post-COVID recovery), while the largest withdrawal was in 2021-22.

(c) Data is sourced from NSDL, the official depository for FPI reporting in India. Note that these figures represent net equity investments only and do not include debt or other instruments.

Overview Of DII Investments In The Indian Stock Market (2010–September 2025)

DIIs in India primarily include mutual funds, insurance companies, banks, and pension funds. Their investments in the Indian stock market, particularly in the equity (cash) segment, have shown a consistent upward trend over the years, often counterbalancing FII outflows. The data below represents annual net investments (gross purchases minus gross sales) in Rs crore, based on trading activity across NSE, BSE, and MSEI. These figures are for calendar years, with 2025 data being provisional and up to September 7, 2025.

DIIs have increasingly played a stabilising role, with net inflows growing from modest levels in the early 2010s to record highs in recent years, driven by rising domestic savings channeled through mutual funds and retirement funds. Cumulative net DII investment from 2010 to September 2025 exceeds Rs 20 lakh crore.

YearDII Net Investment (Rs Crore)
2010-18,632.06
201129,482.13
2012-55,800.09
2013-72,370.68
2014-29,648.30
201564,653.11
201640,080.69
201789,211.41
201896,645.92
201946,914.90
2020-46,040.77
202192,405.59
2022274,737.25
2023182,184.60
2024503,381.22
2025 (up to Sep 7)362,390.72

Key Trends And Insights

(a) Early 2010s (2010–2014): DIIs were net sellers overall, with outflows peaking in 2013 at Rs 72,371 crore, as domestic funds focused on fixed income amid volatile equity markets.

(b) Mid-2010s Recovery (2015–2019): Inflows turned positive, averaging around Rs 67,000 crore annually, supported by economic growth and increasing SIP (Systematic Investment Plan) inflows into mutual funds.

(c) Pandemic and Post-Pandemic (2020–2022): A brief net outflow in 2020 due to redemptions during COVID-19, followed by strong recovery with Rs 2.75 lakh crore in 2022—the highest until then—amid retail investor surge.

(d) Recent Years (2023–2025): Record inflows, with 2024 marking the peak at Rs 5.03 lakh crore. In 2025 so far, DIIs have invested Rs 3.62 lakh crore, offsetting FII outflows and supporting market resilience despite global uncertainties.

(e) Cumulative Impact: DII holdings in Indian equities have risen from about 5–6% in 2010 to over 17% by mid-2025, surpassing FII holdings in some metrics.

Data sourced from aggregated trading activity reports. Negative values indicate net selling. For real-time updates, refer to NSE or BSE official reports.

Comparison Between FII And DII Activity In The Indian Stock Market (2020–2025)

FIIs and DIIs play contrasting roles in the Indian equity market. FIIs often drive volatility with their global fund flows, leading to net withdrawals (outflows) during uncertain periods, while DIIs, including mutual funds and insurance companies, provide stability through consistent investments, especially via SIPs. The table below shows yearly net investments in the equity (cash) segment in Rs crore (positive for net inflows/investments, negative for net outflows/withdrawals). Data for 2025 is provisional up to September 7, 2025. FII withdrawals are highlighted where net is negative, indicating selling pressure offset by DII buying.

YearFII Net (Rs Crore)DII Net (Rs Crore)Key Notes
2020172,849-46,041FII inflows supported market recovery post-COVID crash; DIIs saw minor net outflow amid redemptions.
202125,76892,406Modest FII inflows amid global recovery; DIIs ramped up buying.
2022-121,500274,737Significant FII withdrawals (Rs 1.22 lakh crore) due to rising US rates and Ukraine war; DIIs absorbed with record inflows.
2023174,963182,185Strong FII inflows (Rs 1.75 lakh crore) on India’s growth story; DIIs continued steady support.
202426,565503,381Mild FII inflows despite mid-year volatility; DIIs hit all-time high inflows (Rs 5.03 lakh crore), surpassing FIIs.
2025 (up to Sep 7)-142,892362,391Heavy FII withdrawals (Rs 1.43 lakh crore) amid global uncertainties and high valuations; DIIs invested Rs 3.62 lakh crore, stabilizing the market.

Key Insights

(a) FII Withdrawals Impact: FIIs were net sellers in 2022 and 2025, withdrawing over Rs 2.64 lakh crore combined, often triggering corrections (e.g., Nifty fell ~12% in 2022). However, inflows in 2020 and 2023 (total ~Rs 3.47 lakh crore) fueled bull runs.

(b) DII Counterbalance: DIIs have been net buyers every year except 2020, with cumulative inflows exceeding Rs 13.7 lakh crore from 2020–2025. Their 2024 and 2025 activity (over Rs 8.65 lakh crore combined) highlights rising domestic participation, reducing reliance on FIIs.

(c) Overall Trend: DII holdings rose from ~12% in 2020 to >17% by mid-2025, overtaking FIIs in some metrics. This shift has made the market more resilient to FII outflows.

Data sourced from NSE/BSE trading reports, NSDL, and aggregated market analyses. Figures are approximate and subject to minor revisions; negatives for FII indicate withdrawals. For latest, check NSE India.

Conclusion

A DII-driven bubble in the Indian stock market is a genuine and serious concern, particularly in overheated segments like IPO, small- and mid-caps, etc where valuations outpace fundamentals. Risks include overvaluation, retail overexposure, and potential liquidity shocks. Investors should remain cautious, prioritise fundamentals, and avoid speculative bets to navigate potential volatility.

The fact that FIIs are net sellers in the last four out of five years and DIIs are net buyers in the last five years, cannot be ignored. There is a clear trend that is hinting towards a formation of a Risky DII Bubble says Praveen Dalal.

Posted in Global ODR News | Comments Off on The Risks Of The DII Bubble In India’s Stock Market: Crucial Insights From Praveen Dalal

DII Bubble In Stock Market Of India Is Very Risky Says Praveen Dalal

Note: The term “DII Bubble” has been coined by Praveen Dalal, CEO of Sovereign P4LO.

It refers to the significant increase in investments by Domestic Institutional Investors (DIIs) in the Indian stock market, which has raised concerns about potential overvaluation. As DIIs have been buying aggressively, their share in the market has surpassed that of Foreign Institutional Investors (FIIs), leading to discussions about whether this trend indicates a bubble.

Overview Of Domestic Institutional Investors (DIIs)

DIIs include entities like mutual funds, insurance companies, public sector banks, and pension funds that invest in the Indian stock market. They have gained significant influence, especially in recent years, as their share of the market has increased.

DII Market Share Growth

As of March 31, 2025, DIIs held 17.62% of the Indian capital market, surpassing Foreign Institutional Investors (FIIs) at 17.22%. DII holdings reached ₹71.76 lakh crore, which is 2% higher than FII holdings.

Recent Trends In DII Investments

DIIs have shown resilience despite challenges such as high valuations and foreign selling. Their inflows have been substantial:

In 2025, DIIs invested ₹5.13 lakh crore in the first eight months, nearly tripling the ₹1.81 lakh crore from 2023. Monthly inflows have varied, with significant investments in January (₹86,591 crore) and August (₹94,828 crore).

Factors Driving DII Confidence

Increased retail investor participation has bolstered DII confidence. Despite foreign selling, DIIs have maintained a strong presence, cushioning the market’s volatility.

Concerns About A Potential Bubble

While DIIs are currently strong players in the market, concerns about a bubble exist:

The Price to Earnings (PE) ratio for the NIFTY 50 index has been historically high, indicating potential overvaluation. The Market Capitalisation to GDP ratio is at a 13-year high, suggesting that the stock market may be larger than the underlying economy can support.

In other words, while DIIs are currently thriving and driving market activity, the high valuations and economic indicators raise questions about the sustainability of this growth.

When A DII Bubble Occurs

A DII bubble occurs when sustained DII investment props up overvalued stock markets, masking underlying issues and leading to sharp corrections when the market eventually bursts. While DIIs, such as mutual funds, insurance companies (like LIC), and banks, have historically provided stability, their significant buying can inflate valuations, especially when FIIs are exiting due to high domestic valuations or global factors. If market realities set in, such as an economic slowdown or global recession, and these DII-managed funds face large-scale redemptions, they can quickly shift from being buyers to sellers, intensifying market declines and creating a bubble.

How A DII Bubble Forms

(a) FII Outflows: Foreign investors may leave the Indian market due to factors like high local valuations, rising global interest rates, or a shift to safer assets.

(b) DII Inflows: Domestic institutional investors (DIIs) step in to buy the shares that FIIs are selling, often driven by their mandate to invest domestically or to support the market.

(c) Inflated Valuations: This sustained DII buying can keep stock prices elevated or push them higher, even when the underlying economic fundamentals don’t justify these valuations.

(d) Bubble Creation: By masking these issues, DIIs can unintentionally fuel an asset bubble, where asset prices far exceed their intrinsic worth.

(e) Market Correction: The bubble is prone to bursting when investors (including DIIs) realise the market is overvalued, or when external economic shocks occur. This realisation can trigger panic selling, causing market declines to accelerate.

Dangers For DIIs

(a) Losses for Long-Term Holders: DIIs, which manage funds for long-term investors such as policyholders and pension fund subscribers, are at risk of significant losses when a market correction occurs.

(b) Exacerbated Declines: If a crisis hits, and DIIs need to sell to meet redemption requests, their selling can worsen market downturns, making the correction more severe.

The Indian Context

In recent periods, particularly in early to mid-2025, DIIs have been instrumental in absorbing significant foreign outflows, helping to stabilize the Indian market and even push the overall ownership of Indian companies into DII hands. However, this strong domestic buying can also contribute to market overheating if FII exits continue, potentially creating a situation ripe for a sharp correction.

Let us now discuss in detail why a DII-Driven Bubble could be risky.

(1) Overvaluation Of Stocks

(a) DIIs have significantly increased their investments in Indian equities, with their share in NSE-listed companies reaching an all-time high of 17.62% by March 31, 2025, surpassing FIIs at 17.22%. Heavy DII buying, especially through Systematic Investment Plans (SIPs) and mutual funds, has driven market resilience despite FII outflows. However, this sustained inflow can push valuations to unsustainable levels, particularly in mid- and small-cap stocks, which have seen sharp rises (e.g., Nifty Smallcap 250 up 60% in a year compared to Nifty 50’s 28%).

(b) High valuations, with India’s market cap-to-GDP ratio at a 13-year high of 115% in 2021, suggest stocks may be overpriced relative to economic output. If DIIs continue to pour money into overvalued segments, a correction could wipe out gains, especially for retail investors chasing momentum.

(2) Retail Investor Overexposure

(a) DIIs, particularly mutual funds, rely on retail money through SIPs, which saw net inflows of ₹1.16 lakh crore in Q1 2025. The influx of retail investors, with 6.3 million new demat accounts added from April to September 2020, fuels speculative buying. Social media and financial influencers amplify this, creating a perception that markets only go up, which could lead to irrational exuberance.

(b) If a bubble bursts, retail investors, who often lack the expertise or risk management of DIIs, could face significant losses, eroding confidence and savings.

(3) Market Dependence On DII Inflows

DIIs have acted as a stabilising force, countering FII sell-offs (e.g., ₹55,595 crore invested in March 2020 when FIIs were net sellers). However, this creates a dependency where markets may not correct naturally, masking underlying weaknesses. If DII inflows slow due to economic shocks or policy changes, markets could face sharp declines, as seen during past FII outflows triggered by global events or tighter RBI policies.

(4) Sector-Specific Froth

SEBI’s chairperson flagged “pockets of froth” in small- and mid-cap segments, hinting at a potential bubble. DIIs have increased allocations to sectors like Consumer Discretionary (15.27% of holdings in Q2 2024), which may be overvalued due to speculative buying. A correction in these segments could ripple across the market, impacting DII-heavy portfolios.

(5) Economic And Policy Risks

High inflation, tighter RBI monetary policies, or global events like U.S. interest rate hikes could reduce liquidity, prompting DIIs to scale back investments. This could trigger a sell-off, especially if corporate earnings fail to justify current valuations. For instance, weak corporate earnings in 2024 contributed to market volatility despite DII support.

(6) Risks Mitigated By DII Characteristics

(a) Long-Term Focus: DIIs, unlike speculative retail traders, base decisions on fundamentals, economic outlook, and corporate performance, which reduces the risk of irrational price surges.

(b) Diversified Portfolios: DIIs spread investments across sectors and asset classes, minimizing systemic risk from a single sector’s collapse.

(c) Liquidity Support: DIIs enhance market liquidity, ensuring smoother transactions even during FII outflows, which helps prevent panic-driven crashes.

Critical Perspective

While DII inflows have driven market resilience, the risk of a bubble cannot be dismissed entirely. The “bubble triangle” (marketability, cheap money, speculation) outlined by Quinn and Turner applies partially: trading apps and low-cost brokerages have increased market access, low interest rates have fueled investments, and retail speculation is rising. The real risk lies in specific segments (e.g., small-caps, IPOs) rather than the broader market. A sudden shift in sentiment, triggered by global shocks or policy tightening, could expose vulnerabilities.

Recommendations For Investors

(a) Focus on Fundamentals: Invest in companies with strong earnings, reasonable valuations, and sustainable growth, as DIIs do, rather than chasing momentum.

(b) Diversify: Spread investments across sectors to mitigate risks from overvalued segments like small-caps.

(c) Monitor Triggers: Watch for U.S. interest rate hikes, RBI policy changes, or weak corporate earnings, which could prompt DII pullbacks.

(d) Stay Informed: Track DII and FII activity on trusted platforms for insights into market sentiment.

Conclusion

A DII-driven bubble in the Indian stock market is a genuine and serious concern, particularly in overheated segments like IPO, small- and mid-caps, etc where valuations outpace fundamentals. Risks include overvaluation, retail overexposure, and potential liquidity shocks. Investors should remain cautious, prioritise fundamentals, and avoid speculative bets to navigate potential volatility.

Posted in Global ODR News | Comments Off on DII Bubble In Stock Market Of India Is Very Risky Says Praveen Dalal

Largest Generic Drug Producers In The World (2025)

As of 2025, the global generic drug industry is dominated by a handful of major players, primarily measured by annual revenue from their pharmaceutical operations (based on FY2024 figures, as these inform 2025 rankings). Generic producers focus on affordable alternatives to branded drugs, with many companies headquartered in India, the U.S., Europe, and Israel. The market is driven by patent expirations, rising demand for cost-effective medications, and expansions in biosimilars and complex generics.

Key trends in 2025 include increased competition from Indian firms in emerging markets, regulatory approvals for biosimilars, and supply chain shifts toward U.S. and European manufacturing. Total global generic drug market size is estimated at over $500 billion, with growth projected at 6-8% CAGR through 2030.

Also See

(1) Key Investments By Indian Pharmaceutical Companies In The U.S. In 2025

(2) Acquisitions By Pharmaceutical Companies Of India In United States In 2025

(3) Increase In Generic Drug Manufacturing Capacity Of US In 2025

Below is a ranked list of the top 10 largest generic drug producers by FY2024 revenue. Rankings prioritise companies where generics form the core business (excluding diversified pharma giants like Pfizer or J&J, which have generic segments but focus on innovators). Revenues are approximate and converted to USD where needed; some include biosimilars and APIs as part of generic operations.

RankCompanyHeadquartersFY2024 Revenue (USD)Key Notes
1Teva Pharmaceutical IndustriesIsrael$16.54 billionWorld’s largest generic maker by volume; portfolio of ~3,500 products across 60 markets; strong in U.S. with recent approvals for complex generics like Tofacitinib.
2ViatrisUnited States$15.43 billionFormed from Mylan-Upjohn merger; serves 1 billion patients annually; key approvals for generics of Restasis and Symbicort; focuses on complex products like injectables.
3Sandoz GroupSwitzerland$10.40 billionNovartis spin-off; leader in biosimilars and antibiotics; ~1,500 products delivering $18 billion in savings; expanded penicillin production in 2023.
4Fresenius KabiGermany~$9 billion (est. from segment)Specializes in IV generics, oncology, and critical care; part of Fresenius SE; launched Zinc Sulfate and Vasopressin in 2023; strong in Europe and U.S. injectables.
5Sun Pharmaceutical IndustriesIndia$6.06 billionFourth-largest specialty generic firm; 43 facilities, >1,000 products in 100+ countries; U.S. approvals for lenalidomide and mesalamine; invested 6.7% of revenue in R&D.
6Aurobindo PharmaIndia$3.62 billionFocus on APIs and complex formulations; top in Europe generics; approvals for saxagliptin and injectable suspensions; strong U.S./EU presence with peptide APIs.
7PerrigoIreland (U.S. ops)$4.37 billionConsumer healthcare and Rx generics; emphasis on OTC and store-brand generics; diversified into self-care products.
8STADA ArzneimittelGermany$4.04 billionEuropean leader in generics and OTC; focus on biosimilars and consumer health; acquired brands in emerging markets.
9Dr. Reddy’s LaboratoriesIndia$3.35 billionAPIs, generics, and biosimilars; North America generics hit $1B+; launched Revlimid generic; billion-dollar branded generics in India/emerging markets.
10CiplaIndia$3.16 billionComplex generics in respiratory and HIV; 47 facilities, >1,500 products in 85 markets; U.S. growth in differentiated assets like lanreotide.

Other notable players include Lupin ($2.55 billion, cardiovascular/respiratory focus), Hikma (~$3 billion, injectables/Middle East), and Alkem Laboratories (~$1.5 billion, strong Indian market share). Rankings can vary by metric (e.g., market share vs. revenue), with Indian firms leading in volume but trailing in revenue due to lower pricing in domestic markets. For instance, a 2025 market share analysis highlights Alkem (6.9%), Teva (6.4%), and Cipla (5.8%) as leaders in certain segments.

Posted in Global ODR News | Comments Off on Largest Generic Drug Producers In The World (2025)

Increase In Generic Drug Manufacturing Capacity Of US In 2025

In 2025, the US generic drug manufacturing sector has seen notable expansions and investments, driven primarily by new tariffs, policy initiatives to onshore production, and efforts to address drug shortages and supply chain vulnerabilities. These developments aim to reduce reliance on foreign imports, particularly from China and India, which dominate global API and generic production. The push for domestic capacity is part of broader national security and economic strategies, with announcements totaling billions in commitments. However, actual capacity increases may lag due to implementation timelines, with some experts estimating 3-7 years for full scaling. Idle existing facilities also offer quick-win opportunities, as studies indicate up to 49% of US generic manufacturing capacity was underutilized pre-2025, potentially adding 30 billion doses without new builds.

Key Drivers Of Capacity Increases

(1) Tariffs and Trade Policies: Starting September 1, 2025, the US imposed a “Most Favored Nation” (MFN) tariff on generic pharmaceuticals and APIs, incentivizing domestic production by raising import costs. This has spurred investor interest and reshoring efforts, though it may initially raise prices for generics. The Trump administration’s policies, including Executive Order 14297, emphasize “made in America” drugs, with potential Section 232 tariffs under Commerce Department review.

(2) Legislative and Federal Initiatives: Congressional bills and hearings, such as the House Energy and Commerce Subcommittee’s June 2025 session, advocate for public-private partnerships, tax incentives, and grants to boost generic manufacturing. The American-Made Medicines Caucus, launched in April 2025, focuses on preserving access and expanding capacity. Federal funding for advanced technologies like continuous manufacturing aims to cut costs and enhance sustainability.

(3) Drug Shortages and Supply Chain Resilience: With 270 active shortages in early 2025 (over 80% generics), increased domestic output is prioritized for essential medicines. Brookings and USC reports highlight vulnerabilities to China, pushing for revitalization as a national security imperative.

Major Investments And Expansions In 2025

Several companies announced or advanced capacity boosts, focusing on injectables, biosimilars, and essential generics. Below is a summary of key developments:

CompanyInvestment AmountDetailsTimeline/Impact
Hikma Pharmaceuticals$1 billionExpanding R&D and manufacturing for essential generics, including injectables; adds to existing US facilities in New Jersey and Ohio.By 2030, with initial phases in 2025-2026; aims to increase output of shortage-prone drugs.
Amphastar PharmaceuticalsNot specified (quadrupling capacity)Quadrupling domestic manufacturing for generics, focusing on APIs and finished products.Announced July 2025; rapid scaling using existing sites.
AstraZeneca$50 billionBroad US manufacturing expansion, including generics and biosimilars; part of tariff-response investments.Multi-year, with 2025 site upgrades.
Johnson & Johnson$55 billionDomestic production boost, incorporating generic segments via partnerships.Ongoing in 2025, targeting supply chain resilience.
RocheNot specifiedUS manufacturing investments, including generics through partnerships.Specified in May 2025; focuses on injectables.
Novo NordiskNot specifiedExpansion in generics and injectables manufacturing.Part of broader US investments in 2025.

These investments could collectively add billions of doses annually, with a focus on high-risk categories like antibiotics and oncology drugs. Generic manufacturers like Teva and Viatris are also repurposing idle capacity, potentially increasing output by 57% within one year at surveyed sites.

Also See

(1) Key Investments By Indian Pharmaceutical Companies In The U.S. In 2025

(2) Acquisitions By Pharmaceutical Companies Of India In United States In 2025

Market Context And Projections

The US generic market is projected to grow from $133.59 billion in 2023 to $188.44 billion by 2032 (CAGR 3.5%), but capacity expansions are uneven due to pricing pressures and consolidation. Globally, generics hit $515.07 billion in 2025, with US onshore efforts contributing to a shift from offshore dominance. Challenges include rising costs from tariffs (potentially increasing prices short-term) and the need for 3-7 years to fully ramp up. Innovations like 3D printing and continuous manufacturing are expected to enhance efficiency, supporting further growth into 2030.

Overall, 2025 marks a pivotal year for US generic capacity, with policy-driven investments laying the groundwork for long-term resilience, though full impacts may emerge post-2025.

Posted in Global ODR News | Comments Off on Increase In Generic Drug Manufacturing Capacity Of US In 2025

Monthly Imports By India From The United States (January To July 2025)

The following is the monthly imports by India from the United States (January to June 2025):

MonthValue (millions of USD)
January3,204.4
February3,495.0
March3,768.3
April3,959.6
May3,819.1
June3,805.8

Total (January to June 2025): 22,052.2 million USD ($22.05 billion)

As of September 2, 2025, official data from the U.S. Census Bureau is available only up to June 2025. Data for July is expected to be released on September 4, 2025, and data for August and September is not yet available (September is ongoing). Indian sources indicate July imports at approximately $4.55 billion.

So total imports by India from U.S. from January to July 2025 stands at USD 26.6 billion.

Let us now analyse the monthly imports by India from the United States in 2024. The same is as follows:

MonthValue (millions of USD)
January2,794.8
February2,904.0
March4,078.3
April3,383.5
May3,706.0
June4,052.7
July3,224.3
August4,098.4
September3,348.0
October3,075.3
November3,647.5
December3,224.2

Total (2024): 41,537.0 million USD ($41.54 billion)

This data is based on official records from the U.S. Census Bureau.

So total imports by India from U.S. in the corresponding period of January to July 2024 stands at 24.14 billion USD.

In conclusion, imports by India from U.S. in same period of 7 months (Jan to July 24 vs 25) have increased by 2.46 billion USD. This is despite the fact that U.S. has imposed 50% tariff upon Indian exports to U.S.

Posted in Global ODR News | Comments Off on Monthly Imports By India From The United States (January To July 2025)

Overview Of FII Investments In India (May To September 2025)

Foreign Institutional Investors (FIIs, also referred to as FPIs) showed mixed activity in the Indian market during this period, with net inflows in May and June turning to significant outflows from July onward. Total net FII equity investments were positive early on but turned negative overall, driven by global factors like US tariffs, inflation concerns, and sector-specific shifts. Data is primarily month-wise, as sector breakdowns are reported that way. We have compiled sector-wise net investments (buys positive, sells negative) based on available reports. Amounts are in ₹ crore unless noted otherwise; conversions from USD use approximate rates (~₹83-84/$).

Note: September data is limited (as of Sep 2, 2025), showing continued outflows but no detailed sector breakdown yet. Aggregates exclude debt; focus is on equities.

May 2025: Net Inflow (~₹21,445 to ₹36,299 Cr Total, Per Sources)

FIIs were net buyers, focusing on growth sectors amid post-election optimism. Top buys:

SectorNet Investment (₹ Cr)
Telecom+8,089
Financial Services+4,028 to +4,728 (first half)
Capital Goods+2,233 (first half)
Oil, Gas & Consumable Fuels+2,130 (first half)
Services+1,762 (first half)
Automobile & Auto Components+1,610 (first half)

No major sells reported for May.

June 2025: Net Inflow (~₹8,710 Cr Total)

Continued buying in cyclical and defensive sectors, though with some sells in utilities and consumer goods. Amounts in USD converted to ≈₹ Cr.

SectorNet Investment (₹ Cr approx.)
BFSI (Banking, Financial Services & Insurance)+8,700 ($1,042M)
Oil & Gas+6,000 ($716M)
Automobiles+4,600 ($553M)
Telecom+2,700 ($320M)
Chemicals+2,300 ($278M)

Top sells:

  • Power: -6,100 ($735M)
  • FMCG: -3,900 ($463M)
  • Consumer Durables: -2,400 ($290M)
  • Capital Goods: -1,800 ($215M)
  • Pharma: -400 ($47M)

July 2025: Net Outflow (~₹35,000 Cr Total, Or $4.17B)

Heavy selling amid global risk-off, with IT leading due to declining ownership (from 10.3% to 7.4%) .

SectorNet Investment (₹ Cr)
IT-19,901
Financials-5,900
Realty-3,933
Auto-3,584
Oil & Gas-3,272
Consumer Durables-2,614
Construction-1,354

No major buys reported.

August 2025: Net Outflow (~₹47,000 Cr Total)

Continued heavy selling, with ~₹31,889 Cr out in the first half alone across 8 sectors. Full-month sector data incomplete, but trends suggest persistence in financials, IT, and energy.

First half sells:

SectorNet Investment (₹ Cr)
Financial Services-13,471
IT-6,380
Oil, Gas & Consumable Fuels-4,091
Power-2,358
Healthcare-2,095
Realty, FMCG, Consumer DurablesEach > -1,000 (exact not specified)

No buys highlighted; overall caution due to tariffs and GDP data .

September 2025 (As Of Sep 2): Net Outflow (Amount Unspecified, But Ongoing)

No sector-wise data available yet, but market reports indicate continued FII selling amid value buying in broader indices and strong GDP figures (Doubtful GDP Figures, We Do Not Endorse The Same) . Total outflows persist from August trends.

Key Trends Across The Period

(a) Positive Focus (May-June): FIIs favored BFSI/Financials, Telecom, Oil & Gas, Autos, and Chemicals for growth potential.

(b) Negative Shift (July-Sep): Heavy exits from IT, Financials, Oil & Gas, Realty, Auto, Power, and Healthcare, reflecting risk aversion.

(c) Overall: Net outflows dominate the later period, with DIIs countering to stabilise markets .

Posted in Global ODR News | Comments Off on Overview Of FII Investments In India (May To September 2025)

Acquisitions By Pharmaceutical Companies Of India In United States In 2025

In 2025, prominent Indian pharmaceutical companies like Sun Pharma, Zydus Lifesciences, and Syngene continued their US expansion through strategic acquisitions and investments, such as Sun Pharma’s purchase of Checkpoint Therapeutics for oncology assets, Zydus Lifesciences’ acquisition of a US manufacturing facility for biologics, and Syngene’s first US biologics manufacturing site. These strategic moves, including acquisitions of specific companies, product lines, and manufacturing capabilities, allowed Indian firms to hedge against market volatility, improve health security, diversify production, and gain market access in the United States.

Key Investments By Indian Pharmaceutical Companies In The U.S. In 2025

Below mentioned chart shows a comprehensive list of confirmed acquisitions (completed or announced) by Indian pharmaceutical companies involving U.S.-based companies, assets, or facilities in 2025, up to August 31, 2025. This includes full company takeovers, manufacturing sites, and regulatory assets like ANDAs (Abbreviated New Drug Applications) approved by the U.S. FDA. We have focused on deals with clear U.S. ties, excluding plans or unconfirmed discussions (e.g., BDR Pharmaceuticals’ $100M expansion intent). The general trends show Indian firms leveraging cash reserves for US expansion amid regulatory shifts and biosimilar demand.

Drivers Of These Acquisitions

(a) Market Uncertainty: Acquisitions allow Indian companies to hedge against potential market uncertainties and regulatory challenges in their home market.

(b) Health Security: Expanding manufacturing facilities and diversifying production locations within the US contribute to health security.

(c) Market Access And R&D: These strategic moves enhance market access and align with the Indian government’s goal of strengthening research and development capabilities for new drugs.

(d) Consolidation: The industry saw consolidation, with companies merging to gain scale and efficiency.

(e) Strategic Focus: Many deals target biosimilars, generics, and manufacturing to capitalize on US market growth (e.g., oncology, immunotherapy) while hedging against domestic risks. Indian firms hold record cash piles (~Rs 10,200 crore increase in FY25 alone), fueling this spree.

(f) Potential Risks: U.S. policy changes (e.g., executive orders on generics) could spotlight India’s role in global supply chains. However, these acquisitions strengthen resilience.

Scale And Impact

Total deal value from listed acquisitions exceeds $1.8 billion. No major Torrent Pharma US deals in 2025; focus was on Indian acquisitions like JB Chemicals. There seems to be an “overseas acquisition spree” by firms like Intas and Zydus. In essence, 2025 marked a strategic period where Indian pharmaceutical firms strengthened their foothold in the US by acquiring specific assets and capabilities, rather than solely focusing on traditional export models.

Posted in Global ODR News | Comments Off on Acquisitions By Pharmaceutical Companies Of India In United States In 2025